AstraZeneca Streamlines Further With Sale Of US Entocort Rights
This article was originally published in Scrip
Continuing an effort to streamline assets, AstraZeneca PLC has divested US rights for its inflammatory bowel disease product Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus. The sale, announced Nov. 23 for which Perrigo Company PLC paid $380m, follows the UK-based group's divestment in July of global rights to Entocort, excluding the US, to Tillotts Pharma AG for $215m in cash.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.